OKYO Pharma Future Growth

Future criteria checks 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for OKYO Pharma.

Key information

n/a

Earnings growth rate

n/a

EPS growth rate

Biotechs earnings growth	28.3%
Revenue growth rate	n/a
Future return on equity	n/a
Analyst coverage	Low
Last updated	24 Oct 2024

Recent future growth updates

No updates

Recent updates

Earnings and Revenue Growth Forecasts

NasdaqCM:OKYO - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
3/31/2025	N/A	-15	N/A	N/A	1
3/31/2024	N/A	-17	-9	-9	N/A
3/31/2023	N/A	-13	-8	-8	N/A
12/31/2022	N/A	-11	-7	-7	N/A
9/30/2022	N/A	-7	-5	-5	N/A
6/30/2022	N/A	-6	-5	-5	N/A
3/31/2022	N/A	-5	-5	-5	N/A
12/31/2021	N/A	-5	-5	-5	N/A
9/30/2021	N/A	-5	-4	-4	N/A
6/30/2021	N/A	-4	-3	-3	N/A
3/31/2021	N/A	-3	-2	-2	N/A
12/31/2020	N/A	-2	-1	-1	N/A
9/30/2020	N/A	0	-1	-1	N/A
6/30/2020	N/A	-1	-1	-1	N/A
3/31/2020	N/A	-2	-1	-1	N/A
12/31/2019	N/A	-3	N/A	N/A	N/A
9/30/2019	N/A	-5	-2	-2	N/A
6/30/2019	N/A	-5	-2	-2	N/A
3/31/2019	N/A	-5	-2	-2	N/A
12/31/2018	N/A	-4	N/A	N/A	N/A
9/30/2018	N/A	-3	-2	-2	N/A
6/30/2018	N/A	-15	-2	-2	N/A
3/31/2018	N/A	-28	-2	-2	N/A
12/31/2017	N/A	-27	N/A	-1	N/A
9/30/2017	N/A	-26	N/A	-1	N/A
6/30/2017	N/A	-13	N/A	-1	N/A
3/31/2017	N/A	0	N/A	-1	N/A
12/31/2016	N/A	0	N/A	0	N/A
9/30/2016	N/A	-1	N/A	0	N/A
6/30/2016	N/A	-1	N/A	0	N/A
3/31/2016	N/A	-1	N/A	-1	N/A
9/30/2015	N/A	-1	N/A	-1	N/A
6/30/2015	N/A	-1	N/A	-1	N/A
3/31/2015	N/A	-1	N/A	-1	N/A
12/31/2014	N/A	-6	N/A	-2	N/A
9/30/2014	N/A	-4	N/A	-3	N/A
6/30/2014	N/A	-9	N/A	-3	N/A
3/31/2014	N/A	-14	N/A	-3	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if OKYO's forecast earnings growth is above the savings rate (2.6%).

Earnings vs Market: Insufficient data to determine if OKYO's earnings are forecast to grow faster than the US market

High Growth Earnings: Insufficient data to determine if OKYO's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: Insufficient data to determine if OKYO's revenue is forecast to grow faster than the US market.

High Growth Revenue: OKYO is forecast to have no revenue next year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if OKYO's Return on Equity is forecast to be high in 3 years time

OKYO Pharma Future Growth

Future criteria checks 0/6

Key information

Recent future growth updates

Recent updates

OKYO Pharma Limited Announces First Patient Dosed in the First Clinical Trial to Treat Neuropathic Corneal Pain

OKYO Pharma Limited Announces Start of Phase 2 Clinical Trial to Treat Patients with Neuropathic Corneal Pain

OKYO Pharma Limited announced delayed 20-F filing

OKYO Pharma Announces OK-101 Successfully Achieved Statistical Significance for Multiple Signs and Symptoms of Dry Eye Disease including Ocular Pain Relief in its First-in-Human Phase 2 Trial of OK-101

Okyo Pharma Receives FDA Approval of IND for OK-101 in Neuropathic Corneal Pain

OKYO Pharma Limited Announces Appointment of Scientific Advisory Board

OKYO Pharma Limited Reports Positive Safety and Efficacy Results in Its Phase 2, Randomized, Double-Masted, Placebo-Controlled Trial Evaluating the Safety and Efficacy of OK-101 Ophthalmic Solution in Patients with Dry Eye Disease

OKYO Pharma Limited has filed a Follow-on Equity Offering in the amount of $4 million.

Okyo Pharma Limited Announces Last Patient Enrolled in OK-101 Phase 2 Clinical Trial to Treat Dry Eye Disease Has Completed Final Protocol Visit

OKYO Pharma Limited, Annual General Meeting, Dec 14, 2023

OKYO Pharma Limited has completed a Follow-on Equity Offering in the amount of $1.6389 million.

Okyo Pharma Limited Announces Filing of an Investigational New Drug (Ind) Application for Ok-101 to Treat Neuropathic Corneal Pain

OKYO Pharma Limited Announces Positive Safety Data Profile for the ongoing OK-101 Phase 2 Clinical Trial to Treat Dry Eye Disease (DED)

OKYO Pharma Limited has completed a Follow-on Equity Offering in the amount of $4.000005 million.

OKYO Pharma Limited has completed a Follow-on Equity Offering in the amount of $4.000005 million.

Okyo Pharma Limited Completes Enrollment in Phase 2 Clinical Trial of Ok-101 to Treat Dry Eye Disease

OKYO Pharma Limited announced delayed 20-F filing

OKYO Pharma Limited Plans to Initiate Phase 2 Trial of Ok-101 in Neuropathic Corneal Pain

OKYO Pharma Announces Appointment of William A. Clementi as Chief Operating Officer, Effective September 1, 2023

New minor risk - Shareholder dilution

OKYO Pharma Limited Announces Randomized Segment Now Underway in Phase 2 Clinical Trial of Topical Ocular Ok-101 for Dry Eye Disease

OKYO Pharma's Ordinary Shares of No Par Value, Fully Paid Cancels from Admission to Trading on London Stock Exchange

OKYO Pharma Announces Change of Delisting Date to 22 May 2023

OKYO Pharma Announces U.S. FDA Clearance of IND Application for OK-101 for the Treatment of Dry Eye Disease

OKYO Pharma Limited Announces U.S. IND Filing on Ok-101 for the Treatment of Dry Eye Disease

OKYO Pharma Plans Fourth Quarter 2022 IND Filing of OK-101 to treat Dry Eye Disease with Subsequent Phase 2 Initiation Alongside Peptide Manufacturing Partner, AmbioPharm

OKYO Pharma Limited, Annual General Meeting, Sep 07, 2022

OKYO Pharma Limited announced delayed 20-F filing

OKYO Pharma Limited Announces Successful Completion of A Pre-IND Meeting with the U.S. Food and Drug Administration on the Development of OK-101 to Treat Dry Eye Disease

OKYO Pharma Limited Announces First-in-Class Drug Candidate OK-101 Displaying Both Anti-inflammatory and Ocular Pain-Reducing Potential to Treat Dry Eye Disease

OKYO Pharma Announces Positive Data and Results in an Animal Model Using Topically Administered OK-201 to Treat Neuropathic Ocular Pain

OKYO Pharma Limited Has U.S. Patent Issues Covering its Lipid Conjugated Peptide Analogues for Treating Ocular Pain and Inflammation

Okyo Pharma Limited Announces Filing of A Patent Application Covering the Use of Chemerin and Associated Analogues to Treat “Cytokine Storm” Associated with COVID-19 and ARDS

OKYO Pharma Limited Appoints Gary S. Jacob as Chief Executive Officer

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts

Future Return on Equity

Discover growth companies